The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.
End of content
No more pages to load